Where is Aptevo Therapeutics’ corporate headquarters?
The Company is headquartered in Seattle, Washington. Click here for Company contact information.
Where is Aptevo Therapeutics incorporated?
The Company is incorporated in the state of Delaware.
When did Aptevo Therapeutics spin-off from Emergent BioSolutions? What was the share distribution ratio?
The Company’s spin-off from Emergent BioSolutions occurred on August 1, 2016 and involved a distribution of 100 percent of the Company’s common to Emergent BioSolutions stockholders of record as of July 22, 2016, or the distribution. The share distribution ratio was 1 share of the Company for every 2 shares of Emergent BioSolutions.
Was the spin-off a tax free event for investors?
Except for any cash received in lieu of a fractional ordinary share, we anticipate that a U.S. stockholder generally will not recognize any income, gain or loss as a result of the receipt of the Company’s common shares in the distribution. For more information about the tax consequences of the spin-off, see “Material U.S. Federal Income Tax Consequences” in our information statement, attached as exhibit 99.1 to Company’s Current Report on Form 8-K, filed on August 1, 2016.

YOU ARE URGED TO CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE SPECIFIC TAX CONSEQUENCES TO YOU OF THE DISTRIBUTION, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX RULES AND THE EFFECT OF POSSIBLE CHANGES IN LAWS THAT MAY AFFECT THE TAX CONSEQUENCES DESCRIBED ABOVE.
Where is Aptevo Therapeutics’ stock traded?
The Company’s common stock is traded on the NASDAQ Global Select Market under the ticker symbol “APVO”. Click here to view a stock quote.
What is the CUSIP number of Aptevo Therapeutics’ common stock?
The CUSIP number for the Company’s common stock is 03835L 10 8.
What is Aptevo Therapeutics’ fiscal year?
The Company operates on a calendar quarterly basis, with its year ended December 31.
Who is Aptevo Therapeutics’ transfer agent?
The Company’s transfer agent and registrar is Broadridge Financial Solutions, Inc. They can be contacted at the following:

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
(toll free) 877/830-4936
(international) 720/378-5591
(email) shareholder@broadridge.com
(website) www.broadridge.com/BCIS
Whom do I contact with questions about my stock?
Contact the Company’s transfer agent and registrar as follows:

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
(toll free) 877/830-4936
(international) 720/378-5591
(email) shareholder@broadridge.com
(website) www.broadridge.com/BCIS
How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?
Contact the Company’s transfer agent and registrar as follows:

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
(toll free) 877/830-4936
(international) 720/378-5591
(email) shareholder@broadridge.com
(website) www.broadridge.com/BCIS
Does Aptevo Therapeutics have a direct stock purchase plan?
No, the Company’s stock can only be purchased through a stockbroker or registered investment advisor.
Who is Aptevo Therapeutics’ auditor?
The Company is audited by Ernst & Young LLP.
Does Aptevo Therapeutics pay dividends?
The Company currently intends to retain any and all of its future earnings to finance the growth and development of its business. The Company does not intend to pay cash dividends to its stockholders in the foreseeable future.
Where can I get the latest corporate news releases and financial reports?
The Company’s news releases can be viewed under Press Releases.
How can I view documents Aptevo Therapeutics has filed with the Securities & Exchange Commission (SEC)?
The Company’s filings with the Securities and Exchange Commission can be viewed under SEC Filings.
Who makes up the Aptevo Therapeutics Executive Management team and Board of Directors?
Click here for the Company’s Management Team or Board of Directors.
How can I obtain further information or materials on Aptevo Therapeutics?
For copies of the Company’s Investor information, please click here. For an online version of the Company’s Investor kit, please click here.
Whom should I contact regarding investor inquiries?
All investor inquiries are to be directed to the following:

Jeff Lamothe
Senior Vice President, Chief Financial Officer
Aptevo Therapeutics Inc.
Direct: 206/838-0500
Email: jlamothe@apvo.com